| 摘要 |
Gastric cancer has been one of the ten most frequent cancers and the second leading
cause of cancer-related deaths in the world. In Taiwan, it is the fifth most common
cause of cancer-related deaths, accounting for 6.3% of all cancer deaths. At present
surgery is the only hope of cure but there are still about 40% of patients who die of
recurrent disease. How to extend the patient’s survival after “curative” gastrectomy
becomes a very important issue. Angiogenesis is a crucial phenomenon for tumor
growth and metastasis and anti-angiogenic therapy has become one of targeted
therapies for cancer. It is known that combined anti-angiogenic therapy and
chemotherapy can prolong survival of patients with metastatic colorectal cancer,
but, there is currently no evidence to show that this strategy works for gastric
cancer.
Development of new anti-angiogenic agents and biomarkers of efficacy is ongoing,
and it is expected that anti-angiogenic therapy will be effective in coping with gastric
cancer in the future. This mini-review is written to briefly introduce tumor
angiogenesis and anti-angiogenic therapy in gastric cancer, also discussing the
vascular endothelial growth factor family, and Helicobacter pylori and angiogenesis. |
